Sample records for buserelin

  1. Acute Transverse Myelitis Associated with Buserelin Use during IVF

    Directory of Open Access Journals (Sweden)

    Djavid I. Alleemudder


    Full Text Available A healthy woman undergoing in vitro fertilization (IVF developed acute transverse myelitis (ATM following the use of Buserelin. ATM has a multifactorial etiology and may develop as a result of the activation of immune responses. Infectious agents have been postulated as possible triggers of an immune response (Sá, 2009. Gonadotropin-releasing agonists may have a similar role and trigger the acceleration of preexisting disease by the activation of immune responses (Ho et al., 1995, and Umesaki et al., 1999.

  2. Acute Transverse Myelitis Associated with Buserelin Use during IVF


    Alleemudder, Djavid I.; Khaled Sadek; Shaun Fountain; Sallie Davies


    A healthy woman undergoing in vitro fertilization (IVF) developed acute transverse myelitis (ATM) following the use of Buserelin. ATM has a multifactorial etiology and may develop as a result of the activation of immune responses. Infectious agents have been postulated as possible triggers of an immune response (Sá, 2009). Gonadotropin-releasing agonists may have a similar role and trigger the acceleration of preexisting disease by the activation of immune responses (Ho et al., 1995, and Umes...


    Directory of Open Access Journals (Sweden)

    L. Safdarian


    Full Text Available Pituitary suppression by depot GnRH agonist may be excessive for ovarian stimulation. This study compares the efficacy of a single half-dose depot triptorelin and reduced-dose daily buserelin in a long protocol ICSI/ET. METHODS: A total of 182 patients were randomized into two groups using sealed envelopes. Pituitary desensitization was obtained in group 1 (91 patients with half-dose (1.87 mg depot triptorelin in the mid-luteal phase of their menstrual cycle, and in group 2 (91 patients with standard daily dose (0.5 mg buserelin, which was then reduced to 0.25 mg at the start of human menopausal gonadotropin (HMG stimulation. RESULTS: No significant differences were found among those who received HCG in terms of clinical pregnancy rate (34.4% in both groups, implantation rate (14.8% in group 1 versus 11.1% in group 2, fertilization rate (93.3 versus 95.6%, poor response rate (11.1 versus 6.7%, and miscarriage rate (11.1 versus 7.8%. No significant differences were seen in number of HMG ampoules used, follicles at HCG administration, and oocytes retrieved. The number of days of stimulation was significantly reduced in group 2 (11.2 +/- 1.8 in group 1 versus 10.6 +/- 1.9, p = 0.030. CONCLUSION: A half-dose of depot triptorelin can be successfully used in ovarian stimulation instead of reduced-dose daily buserelin, with more patient comfort and reduced stress and cost of injections.

  4. Impact of Buserelin Acetate or hCG Administration on the Day of First Artificial Insemination on Subsequent Luteal Profile and Conception Rate in Murrah Buffalo (Bubalus bubalis). (United States)

    Pandey, A K; Ghuman, Sps; Dhaliwal, G S; Agarwal, S K; Phogat, J B


    This study was designed to investigate the impact of buserelin acetate (BA) or human chorionic gonadotropin (hCG) administration on the day of first artificial insemination (AI) on subsequent luteal profile (diameter of corpus luteum (CL) and plasma progesterone) and conception rate in Murrah buffalo. The present experiment was carried out at two locations in 117 buffalo that were oestrus-synchronized using cloprostenol (500 μg) administered (i.m.) 11 days apart followed by AI during standing oestrus. Based on treatment (i.m.) at the time of AI, buffalo were randomly categorized (n = 39 in each group) into control (isotonic saline solution, 5 ml), dAI-BA (buserelin acetate, 20 μg) and dAI-hCG (hCG, 3000 IU) group. Out of these, 14 buffalo of each group were subjected to ovarian ultrasonography on the day of oestrus to monitor the preovulatory follicle and on days 5, 12, 16 and 21 post-ovulation to monitor CL diameter. On the day of each sonography, jugular vein blood samples were collected for the estimation of progesterone concentrations. All the buffalo (n = 117) were confirmed for pregnancy on day 40 post-ovulation. The conception rate was better (p  0.05) to exhibit stimulatory impact of treatment on luteal profile when compared to control group. In brief, buserelin acetate or hCG treatment on the day of first AI leads to an increase in conception rate; however, an appreciable impact on post-ovulation luteal profile was observed only in hCG-treated Murrah buffalo. PMID:27170495

  5. Desenvolvimento folicular no pós-parto de vacas da raça Gir tratadas com acetato de buserelina (GnRH ou gonadotrofina coriônica humana (hCG Follicular development in Gir breed cows (Bos indicus treated with buserelin acetate or human chorionic gonadotrophin during the postpartum period

    Directory of Open Access Journals (Sweden)

    Álan Maia Borges


    Full Text Available Foram utilizadas 22 vacas da raça Gir (Bos indicus em anestro pós-parto, amamentando e mantidas sob regime de pastejo. O padrão de crescimento folicular foi estudado em 15 animais, enquanto os outros sete foram utilizados somente no acompanhamento da resposta aos tratamentos hormonais. Ultra-sonografia em tempo real foi realizada diariamente, do quarto ao qüinquagésimo dia de lactação, por meio de aparelho equipado com probe de 5MHz. Nenhum animal apresentou estro, ovulação ou luteinização folicular durante o período de avaliação. Verificaram-se quatro a oito ondas foliculares surgindo em intervalos de seis a sete dias, cujo diâmetro máximo dos folículos dominantes e subordinados foi de 8,9±0,6 e 6,3±0,7mm, respectivamente. Aos 56 dias pós-parto, as 22 vacas foram divididas em dois grupos: 11 tratadas com 4,2 mig de acetato de buserelina e 11 com 3.000UI de hCG. A ovulação, regressão e luteinização folicular foram verificadas em animais dos dois tratamentos e uma nova onda folicular surgiu dentro de dois a três dias após a terapia hormonal. Corpos lúteos de menor tamanho e concentrações de progesterona abaixo de 1ng/mL indicaram baixa atividade luteal.This experiment was carried out with 22 anestrus Gir cows (Bos indicus, with the postpartum follicular growth studied in 15 of these suckling and kept on pasture, while the seven others were used only for hormonal treatments. Daily real time ultrasonography was done from 4th to the 50th day, using B-mode ultrasound scanner equipped with a linear array 5.0MHz probe. No animal showed estrus, ovulation or follicular luteinization during de experimental period. Four to eight follicular waves emerged each six or seven days and maximum diameter of dominant and subordinate follicles were 8.9±0.6mm and 6.3±0.7mm, respectively. On day 56 of postpartum all cows were separated in two groups: 11 cows were treated either with 4.2 mug of buserelin acetate and 11 with 3,000UI of h

  6. Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization


    Hammar, Oskar; Roth, Bodil; Bengtsson, Mariette; Mandl, Thomas; Ohlsson, Bodil


    Background: Prior reports suggest a link between gonadotropin-releasing hormone (GnRH) and gastrointestinal function. The aim of the study was to prospectively investigate women subjected to in vitro fertilization (IVF) using the GnRH analog buserelin, taking into account gastrointestinal symptoms and antibody development against buserelin, GnRH, luteinizing hormone (LH), and their receptors. Methods: Gastrointestinal symptoms were registered by the Visual Analogue Scale for Irritable Bowel S...

  7. MRI evaluation for conservative treatment in endometriosis and uterine myoma

    Energy Technology Data Exchange (ETDEWEB)

    Kasai, Mayumi; Karibe, Akihiko; Sato, Ken; Suzuki, Hirosi; Iida, Hajime (Iwate Prefectural Central Hospital, Morioka (Japan)); Yamaya, Rie


    Eighteen patients with endometriosis or uterine myoma underwent MRI before and after conservative treatment with Danazol (400 mg/day) or Buserelin (900 {mu}g/day) to examine pathological changes. Of 8 patients with endometrial chocolate cyst, 7 patients were given Dazazol for 3 to 7 months, in whom high signal intensity indicative of mass tended to decrease after chemotherapy especially on T2-weighted images. In addition, the area of cyst was reduced by 31% to 100%. In the remaining one patient receiving Buserelin for 8 months, the reduction rate of cyst was 31%. Ten patients with adenomyosis were classified into the group given Danazol for 5 to 15 months (n=4) and the group given Buserelin for 3 to 8 months (n=6). Low intensity area was decreased by 9% to 25% in the Danazol group and by 20% to 69% in the Buserelin group. Uterine area was reduced by 10% to 32% in the Danazol group and by 4.5% to 51% in the Buserelin group. MRI was helpful in the management of these diseases during conservative treatment. (N.K.).

  8. MRI evaluation for conservative treatment in endometriosis and uterine myoma

    International Nuclear Information System (INIS)

    Eighteen patients with endometriosis or uterine myoma underwent MRI before and after conservative treatment with Danazol (400 mg/day) or Buserelin (900 μg/day to examine pathological changes. Of 8 patients with endometrial chocolate cyst, 7 patients were given Dazazol for 3 to 7 months, in whom high signal intensity indicative of mass tended to decrease after chemotherapy especially on T2-weighted images. In addition, the area of cyst was reduced by 31% to 100%. In the remaining one patient receiving Buserelin for 8 months, the reduction rate of cyst was 31%. Ten patients with adenomyosis were classified into the group given Danazol for 5 to 15 months (n=4) and the group given Buserelin for 3 to 8 months (n=6). Low intensity area was decreased by 9% to 25% in the Danazol group and by 20% to 69% in the Buserelin group. Uterine area was reduced by 10% to 32% in the Danazol group and by 4.5% to 51% in the Buserelin group. MRI was helpful in the management of these diseases during conservative treatment. (N.K.)

  9. Intrauterine fertilization capsules--a clinical trial

    DEFF Research Database (Denmark)

    Lenz, S; Lindenberg, S; Sundberg, K;


    Treatment of 26 women with tubal infertility was attempted using intrauterine capsules loaded with oocytes and spermatozoa. The stimulation protocol was as used for in vitro fertilization and embryo transfer and consisted of short-term use of Buserelin, human menopausal gonadotropin, and human ch...

  10. Effects of varying doses of β-nerve growth factor on the timing of ovulation, plasma progesterone concentration and corpus luteum size in female alpacas (Vicugna pacos). (United States)

    Stuart, C C; Vaughan, J L; Kershaw-Young, C M; Wilkinson, J; Bathgate, R; de Graaf, S P


    Ovulation in camelids is induced by the seminal plasma protein ovulation-inducing factor (OIF), recently identified as β-nerve growth factor (β-NGF). The present study measured the total protein concentration in alpaca seminal plasma using a bicinchoninic acid (BCA) protein quantification assay and found it to be 22.2±2.0mgmL(-1). To measure the effects of varying doses of β-NGF on the incidence and timing of ovulation, corpus luteum (CL) size and plasma progesterone concentration, 24 female alpacas were synchronised and treated with either: (1) 1mL 0.9% saline (n=5); (2) 4µg buserelin (n=5); (3) 1mg β-NGF protein (n=5); (4) 0.1mg β-NGF (n=5); or (5) 0.01mg β-NGF (n=4). Females were examined by transrectal ultrasonography at 1-2-h intervals between 20 and 45h after treatment or until ovulation occurred, as well as on Day 8 to observe the size of the CL, at which time blood was collected to measure plasma progesterone concentrations. Ovulation was detected in 0/5, 5/5, 5/5, 3/5 and 0/4 female alpacas treated with saline, buserelin, 1, 0.1 and 0.01mg β-NGF, respectively. Mean ovulation interval (P=0.76), CL diameter (P=0.96) and plasma progesterone concentration (P=0.96) did not differ between treatments. Mean ovulation interval overall was 26.2±1.0h. In conclusion, buserelin and 1mg β-NGF are equally effective at inducing ovulation in female alpacas, but at doses ≤0.1mg, β-NGF is not a reliable method for the induction of ovulation. PMID:24965784

  11. Investigation of Hypothalamus-Pituitary-Gonadal Axis in Epileptic Women Treated for Epilepsy

    Directory of Open Access Journals (Sweden)

    Füsun Ferda Erdoğan


    Full Text Available Objectives: Reproductive endocrine disorders, especially polycystic ovary syndrome (PCOS are common in epileptic women who are less fertile and suffer from more menstrual and reproductive endocrine disorders than non-epileptic women. The etiology of reproductive endocrine dysfunction in epilepsy has not been determined precisely. The aim of the study was to investigate the hypotalamus-pituitary-gonadal axis, insulin resistance and the prevalence of PCOS in patients with generalized idiopathic or cryptogenic epilepsy and receiving treatment with valproate (VPA and carbamazepine (CBZ. Method: This study included 48 epileptic women with a mean age of 24.2±5.5 years. The patient groups consisted of 34 (70.8% women with epilepsy on VPA and 14 (29.2% women with epilepsy on CBZ. The control group consisted of 20 healthy women. Fasting blood samples were obtained for the determination of glucose, insulin, gonadotrophins, estradiol, androgens, 17-OH progesteron (17-OHP, and sex hormone-binding globulin (SHBG levels. All subjects underwent oral glucose tolerance test (OGTT and the buserelin stimulation test for glucose tolerance status, insulin resistance parameters and hypothalamus-pituitary-gonadal axis evaluation. Results: PCOS was diagnosed in 17 (35.4% epileptic patients and glucose intolerance was found in two (4.1% patients. Basal insulin levels, glucose and insulin responses to OGTT were significantly higher in the patients than in the controls. Peak and area under curve (AUC 17-OHP responses to the buserelin stimulation test were significantly higher in the patients than in the controls. Discussion: The prevalence of PCOS among women with epilepsy receiving VPA or CBZ treatment was higher than expected. Those patients had increased ovarian stroma and hormonal activity characterized by hyperandrogenemia, as demonstrated by buserelin testing and insulin resistance as demonstrated by OGTT. (Arc­hi­ves of Neu­ropsy­chi­atry 2012;49: 133-138

  12. Persistent GnRH receptor activation in pituitary αT3-1 cells analyzed with a label-free technology. (United States)

    Nederpelt, I; Vergroesen, R D; IJzerman, A P; Heitman, L H


    The gonadotropin-releasing hormone (GnRH) receptor is a drug target for certain hormone-dependent diseases such as prostate cancer. In this study, we examined the activation profiles of the endogenous ligand, GnRH and a well-known marketed analog, buserelin using a label-free assay in pituitary αT3-1 cells with endogenous GnRH receptor expression. This whole cell impedance-based technology allows for the real-time measurement of morphological cellular changes. Both agonists dose-dependently decreased the impedance as a result of GnRH receptor activation with potencies of 9.3±0.1 (pEC50 value, buserelin) and 7.8±0.06 (pEC50 value, GnRH). Subsequently, GnRH receptor activation was completely abolished with a selective Gαq inhibitor, thereby confirming the Gαq-coupling of the GnRH receptor in pituitary αT3-1 cells. Additionally, we observed continued responses after agonist stimulation of αT3-1 cells indicating long-lasting cellular effects. Wash-out experiments demonstrated that the long-lasting effects induced by GnRH were most likely caused by rebinding since over 70% of the original response was abolished after wash-out. In contrast, a long receptor residence time was responsible for the prolonged effects caused by buserelin, with over 70% of the original response remaining after wash-out. In summary, we validated that impedance-based label-free technology is suited for studying receptor-mediated activation in cell lines endogenously expressing the target of interest. Moreover, this real-time monitoring allows the examination of binding kinetics and its influence on receptor activation at a cellular level. PMID:26774084

  13. Ovary response and embryonic mortality in buffaloes treated with GnRH or hCG


    L. Zicarelli; R. Di Palo; A. Balestrieri; C. Grassi; M. Rendina; Vecchio, D; G. Campanile


    The aim of the present study was to examine whether treatment with a GnRH agonist or hCG in pregnant buffaloes on Day 25 after AI induce ovulation and increased P4 concentrations. The trial was carried out on 98 pluriparous buffaloes (DIM = 163 ± 75 days) diagnosed pregnant by ultrasound on day 25 after AI, and randomly assigned in two treatment groups GnRH (12 μg of Buserelin Acetate i.m) and hCG (1500 I.U. i.m.) after measurements of follicular diameter and evaluated ovulation. Mi...

  14. Fixed-time artificial insemination in beef cattle

    Directory of Open Access Journals (Sweden)

    Taponen Juhani


    Full Text Available Abstract Background The study was designed to test the effect of fixed-time artificial insemination (fixed-AI after the slightly modified Ovsynch protocol on the pregnancy rate in beef cattle in Finnish field conditions. The modification was aimed to optimize the number of offsprings per AI dose. Methods Ninety Charolais cows and heifers were entered into the program an average of 1.8 times. Thus, 164 animal cases were included. Animals were administered 10-12 μg of buserelin. Seven days later animals without a corpus luteum (CL were rejected (20.7% while the remaining 130 cases with a CL were administered prostaglandin F2α, followed 48 h later with a second injection of buserelin (8-10 μg. Fixed-AI was performed 16-20 hours after the last injection. Results The pregnancy rate was 51.5% (67/130. The pregnancy rate after a short interval (50-70 d from calving to entering the program was significantly higher than that after a long interval (>70 d. Conclusion This protocol seems to give acceptable pregnancy results in beef herds and its effect on saving labour is notable.

  15. Comparison of the GnRH-stimulation test and a semiquantitative quick test for LH to diagnose presence of ovaries in the female domestic cat. (United States)

    Rohlertz, M; Ström Holst, B; Axnér, E


    It is generally recommended that female cats not intended for planned breeding are spayed to reduce the population of feral cats and also because spaying is beneficial for the long-term health of the individual. For female cats of unknown origin or with estrous symptoms after spaying there is a need for a reliable method to diagnose or rule out the presence of ovaries to avoid unnecessary surgery. Methods previously recommended include vaginal cytology, evaluation of serum estradiol concentration during suspected estrus, induction of ovulation and subsequent evaluation of progesterone, or explorative laparotomy. These methods have the disadvantages that an accurate diagnosis only can be made during estrus or that an invasive procedure is required. Previously, the use of a GnRH challenge test and a semiquantitative LH test have been reported. Our aim was to compare these two methods. We therefore divided 31 female cats in two groups: (1) intact nonestrous females (N = 16), and (2) previously ovariohysterectomized females (N = 15). A blood sample was collected (Time 0) and 0.4 μg/kg buserelin (Receptal; Intervet, Danderyd, Sweden) was injected im. A new blood sample was collected 120 min after the injection. A drop of serum from the sample collected at Time 0 was placed on the LH test (Witness LH; Synbiotics, Corp., San Diego, CA, USA) and the result was evaluated as negative or positive. The remaining serum was frozen and analyzed for estradiol in one batch. Serum estradiol before buserelin stimulation ranged between 5 and 45 pmol/L (N = 14) in intact nonestrous queens and between 2 and 6 pmol/L (N = 15) in ovariohysterectomized females. Estradiol in samples collected after 120 min ranged between 12 and 51 pmol/L (N = 16) in intact queens and between 1 and 7 pmol/L (N = 15) in spayed cats giving a sensitivity and specificity of 100% for the buserelin stimulation test at a cutoff value of 11 pmol/L. All intact queens were negative in the semiquantitative LH test

  16. Erythropoietin may reduce the risk of germ cell loss in boys with cryptorchidism

    DEFF Research Database (Denmark)

    Cortes, D; Visfeldt, J; Thorup, J M


    infertility. In order to increase the number of germ cells, and thereby the fertility potential, additional hormonal therapy has been attempted before surgery. In a study, small doses of the gonadotropin-releasing hormone analogue buserelin before orchiopexy caused higher values. Others have found that......PURPOSE: In boys with cryptorchidism older than 2 years a testicular biopsy at time of orchiopexy shows lack of germ cells in 10-40% of the cases. The number of spermatogonia per tubule is prognostic for subsequent fertility potential. A biopsy without germ cells is associated with 33-100% risk of...... hormonal treatment with human chorionic gonadotropin or gonadotropin releasing hormone analogue may harm the germ cells in cryptorchidism. The aim of the study is to demonstrate that additional hormonal therapy with erythropoietin has a positive effect on the number of germ cells. MATERIALS AND METHODS...

  17. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty

    DEFF Research Database (Denmark)

    Juul, A; Scheike, Thomas Harder; Nielsen, C T;


    Central precocious puberty (CPP) is characterized by early activation of the pituitary-gonadal axis, which leads to increased growth velocity and development of secondary sexual characteristics. It is generally believed that gonadal sex steroids stimulate pulsatile GH secretion, which, in turn......, stimulates insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) production. However, little is known about GH, IGF-I, and IGFBP-3 serum levels in children with precocious puberty. Treatment of CPP by GnRH agonists has become the treatment of choice. However, the effect of long term...... treatment with GnRH in combination with an antiandrogen (cyproterone acetate) to block the possible effect of adrenal androgens has not previously been evaluated. We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination with...

  18. Premenstrual Exacerbation of Life-Threatening Asthma: Effect of Gonadotrophin Releasing Hormone Analogue Therapy

    Directory of Open Access Journals (Sweden)

    Alun L Edwards


    Full Text Available Variability in the severity of asthma during various phases of the menstrual cycle has been frequently suspected. However, the hormonal changes that might affect mediators of bronchospasm have yet to be elucidated. The case of a 41-year-old woman suffering from longstanding asthma with life-threatening exacerbations is reported. The patient was treated with buserelin, a gonadotropin releasing hormone (GnRH analogue, which created a temporary chemical menopause and thus permitted diagnosis of a premenstrual exacerbation of asthma and offered insight into potential therapy. GnRH analogues may therefore be of value in assessing women with severe asthma suspected to vary with the menstrual cycle. The addition of estrogens and progestins at the same time as treatment with GnRH analogue may be of value in determining the role of these hormones in the pathogenesis of menstrually related exacerbations of asthma.

  19. Reversible estrous cycle suppression in prepubertal female rabbits treated with slow-release deslorelin implants. (United States)

    Geyer, A; Daub, L; Otzdorff, C; Reese, S; Braun, J; Walter, B


    The aim of this study was to examine the long-term effect of a 4.7-mg deslorelin GnRH analog implant on ovarian function in the prepubertal female rabbit. Seven female rabbits (group 1) were treated with the implant at the age of 60 days. The implant was inserted subcutaneously in the umbilical region. Two animals (group 2) were not treated and served as a control group. The vulva of all 9 animals was examined for the presence of typical cyclical changes, additionally the occurrence of mounting behavior was recorded. Ovarian function was checked by administration of a short-acting GnRH agonist to induce ovulation and pseudopregnancy (0.8 μg of buserelin per animal intramuscularly). Ten days after each treatment with buserelin, blood was collected for progesterone measurement to confirm pseudopregnancy. After implant insertion, the first blood collection (Day 10) was done without preceding induction of ovulation to screen for implant induced ovulation and pseudopregnancy. The implant was in situ for 273 days, and during this time span, 12 attempts of induction of ovulation were carried out in intervals of 21 days, beginning at the age of 81 days. Afterward, it was removed under local anesthesia and 3 further inductions of ovulation by the same scheme were conducted. The insertion of the implant led to the establishment of a pseudopregnancy in 2 of 7 animals; the remaining 5 animals did not show elevated progesterone values. Attempts to induce ovulation by administration of the short-acting GnRH analog while the slow-release GnRH analog implant was in place were not successful in treated animals, and progesterone concentrations were basal. The effect was reversible as ovulation could be induced in 2 subsequent cycles in all animals by the third induction of ovulation after implant removal. Induction of ovulation in control animals at the age of 110 and 131 days resulted in elevated progesterone levels after 10 days. No adverse side effects could be observed

  20. Ovary response and embryonic mortality in buffaloes treated with GnRH or hCG

    Directory of Open Access Journals (Sweden)

    L. Zicarelli


    Full Text Available The aim of the present study was to examine whether treatment with a GnRH agonist or hCG in pregnant buffaloes on Day 25 after AI induce ovulation and increased P4 concentrations. The trial was carried out on 98 pluriparous buffaloes (DIM = 163 ± 75 days diagnosed pregnant by ultrasound on day 25 after AI, and randomly assigned in two treatment groups GnRH (12 μg of Buserelin Acetate i.m and hCG (1500 I.U. i.m. after measurements of follicular diameter and evaluated ovulation. Milk samples were collected on Days 30 and 45 after AI, to assess P4 concentrations in whey. Differences between the follicular diameters of ovulation and P4 were tested by ANOVA. The incidences of animals which responded to the two treatments were analysed by Chi square test. The treatments on day 25 after AI induced ovulation respectively in 68.6% (GnRH and 57.4% (hCG of the buffaloes. No differences were found between diameter of follicle ovulated. Ovulation increased milk whey progesterone levels and reduced embryonic mortality in buffalo cows.

  1. Evaluation of Pre and Post Artificial Insemination effect of GnRH Hormone on conception of repeat breeder Deoni Cows

    Directory of Open Access Journals (Sweden)

    S.D. Awati


    Full Text Available Twenty four Deoni repeat breeder cows were randomly allocated into 4 groups of six each. The animals of groups I, II and III were injected with 250 µg of buserelin acetate (Receptal® on two occasions i.e. once on day of estrus and second dose on days 10 or 12 or14 respectively in I, II and III groups following breeding, while the animals of group IV served as control. Among the physical characters of estrual cervico-vaginal mucous, typical arborization pattern (80.95 % in pregnant vs. 55.56 % in non-pregnant cows and marginally high spinnbarkeit readings (24.67+2.7cms in pregnant and 22.21+1.32 cms in non-pregnant cows favored better fertility, although the differences between the groups were statistically insignificant. However, the pH of estrual cervico-vaginal mucous did not indicate any effect on fertility and it ranged between 8.00 to 9.00. The cows of treatment groups I, II and III registered a considerably higher conception rate of 83.33 percent each, while in control group cows had only 33.33 percent. To conclude GnRH therapy irrespective of days of administration resulted in an overall enhancement in conception rate of 83.33 as against 33.33 percent in control groups of cows. [Vet. World 2010; 3(5.000: 209-211

  2. Tratamento endócrino dos meningiomas: uma revisão

    Directory of Open Access Journals (Sweden)

    Luiz Augusto Casulari Roxo Da Motta


    Full Text Available Os meningiomas são tumores benignos do sitema nervoso central. Apresentam altas taxas de recidiva e muitas vezes são considerados inoperáveis, como quando se localizam em local de difícil acesso cirúrgico ou quando englobam estruturas nobres do cérebro. Existem evidências clínicas, epidemiológicas, bioquímicas e de experimentos "in vitro" de que seu crescimento sofre influência do meio hormonal esteróideo. Vários ensaios terapêuticos têm explorado estas características do meningioma através do uso de substâncias que interferem na ação destes esteróides: RU486 (antiprogestínico e antiglicocorticóide, acetato de medroxiprogesterona (antiprogestínico, gestrinona (antiestrogênico e antiprogestínico, tamoxifen (antiestrogênico e buserelin (superagonista do LHRH, além do octreotide (análogo da somatostatina e a bromocriptina (agonista dopaminérgico. Outros medicamentos possuem potencial para o tratamento dos meningiomas: aminoglutetimina, suramin e trapidil. Nesta revisão, analizamos a literatura sobre esses aspectos.

  3. Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation. (United States)

    Duijkers, I J; Vemer, H M; Hollanders, J M; Willemsen, W N; Bastiaans, L A; Hamilton, C J; Thomas, C M; Borm, G F


    The aim of the present study was to investigate whether reducing the amount of luteinizing hormone (LH) in gonadotrophic preparations impairs follicular growth in in-vitro fertilization (IVF) cycles during suppression of endogenous LH levels. A selected group of 20 IVF patients was randomly divided into two groups. One group was treated with Org 31338 [follicle stimulating hormone (FSH)/LH 3:1], the other group with Metrodin (purified FSH), both during pituitary down-regulation with buserelin. A fixed daily dose of 150 IU FSH i.m. was given. Serum concentrations of FSH, LH, oestradiol and progesterone were determined frequently and serial ultrasound examinations were performed. Multiple follicular growth with concomitant rise of oestradiol levels was observed in all cycles. The duration of the stimulation phase was shorter in the group treated with Org 31338 than in the group treated with Metrodin. The number of follicles and oocytes and the fertilization rate was larger and the mean embryo quality was higher in the Org 31338 group, but the differences did not reach statistical significance. No significant differences were found in hormonal values. In women with normal endocrine profiles, lowering of the LH activity in gonadotrophic preparations during gonadotrophin-releasing hormone agonist treatment results in adequate ovarian stimulation. However, a preparation with some LH needed a shorter stimulation than a purified FSH preparation. Whether the other beneficial effects of Org 31338 also occur in a larger population needs further investigation. PMID:8253923

  4. Electromembrane extraction of gonadotropin-releasing hormone agonists from plasma and wastewater samples. (United States)

    Nojavan, Saeed; Bidarmanesh, Tina; Mohammadi, Ali; Yaripour, Saeid


    In the present study, for the first time electromembrane extraction followed by high performance liquid chromatography coupled with ultraviolet detection was optimized and validated for quantification of four gonadotropin-releasing hormone agonist anticancer peptides (alarelin, leuprolide, buserelin and triptorelin) in biological and aqueous samples. The parameters influencing electromigration were investigated and optimized. The membrane consists 95% of 1-octanol and 5% di-(2-ethylhexyl)-phosphate immobilized in the pores of a hollow fiber. A 20 V electrical field was applied to make the analytes migrate from sample solution with pH 7.0, through the supported liquid membrane into an acidic acceptor solution with pH 1.0 which was located inside the lumen of hollow fiber. Extraction recoveries in the range of 49 and 71% within 15 min extraction time were obtained in different biological matrices which resulted in preconcentration factors in the range of 82-118 and satisfactory repeatability (7.1 < RSD% < 19.8). The method offers good linearity (2.0-1000 ng/mL) with estimation of regression coefficient higher than 0.998. The procedure allows very low detection and quantitation limits of 0.2 and 0.6 ng/mL, respectively. Finally, it was applied to determination and quantification of peptides in human plasma and wastewater samples and satisfactory results were yielded. PMID:26799761

  5. Strategies to reduce embryonic mortality in buffalo cows

    Directory of Open Access Journals (Sweden)

    M.J. D’Occhio


    Full Text Available The aim of the present study was to examine whether treatment with a GnRH agonist, hCG or P4 on Day 25 after AI increased P4 concentrations and reduced the incidence of embryonic mortality (EM in pregnant buffaloes mated in mid-winter in a Mediterranean environment. The trial was carried out in two farms characterized, in previous years, by low (LEM Group, 153 buffaloes (DIM=150±7 days, and high (HEM Group, 284 buffaloes (DIM=163±5 days, incidence of embryo mortality. Animals were synchronized by Ovsynch-TAI Program and artificially inseminated. On day 25, pregnant buffaloes were randomly assigned to four groups: Control (no treatment, GnRH agonist (buserelin acetate, 12.6 μg, hCG (1500 IU and P4 (341 mg of P4 i.m. every 4 days for three times. Progesterone (pg/ml was determined in milk whey on Days 10, 20 and 25 after AI in all buffaloes and in Days 30 and 45 only in buffaloes pregnant on day 25 and assigned to four groups of treatment. Pregnancy diagnosis was undertaken on Day 45 by ultrasound. All treatments increased P4 milk whey and reduced embryonic mortality in buffalo cows bred in the farm characterized by high EM.

  6. Antibodies against gonadotropin-releasing hormone (GnRH and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction

    Directory of Open Access Journals (Sweden)

    Montgomery Agneta


    Full Text Available Abstract Background Antibodies against gonadotropin-releasing hormone (GnRH and gastrointestinal dysmotility have been found after treatment with GnRH analogues. The aim of this study was to examine the presence of such antibodies in patients with dysmotility not subjected to GnRH treatment and study the anti-GnRH antibody effect on enteric neurons viability in vitro. Methods Plasma and sera from 3 patients suffering from either enteric dysmotility, irritable bowel syndrome (IBS or gastroparesis were analysed for C-reactive protein (CRP, and for GnRH antibodies and soluble CD40 by ELISA methods. Primary cultures of small intestinal myenteric neurons were prepared from rats. Neuronal survival was determined after the addition of sera either from the patients with dysmotility, from healthy blood donors, antiserum raised against GnRH or the GnRH analogue buserelin. Only for case 1 a full-thickness bowel wall biopsy was available for immunohistochemical analysis. Results All 3 patients expressed antibodies against GnRH. The antibody titer correlated to the levels of CD40 (rs = 1.000, p Conclusion Autoantibodies against GnRH can be detected independently on treatment of GnRH analogue. Whether the generation of the antibody is directly linked to neuron degeneration and chronic gastrointestinal symptoms in patients with intestinal dysmotility, remains to be answered.

  7. Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF

    Directory of Open Access Journals (Sweden)

    Manieri Chiara


    Full Text Available Abstract Background Serum anti-Mullerian hormone (AMH is currently considered the best marker of ovarian reserve and of ovarian responsiveness to gonadotropins in in-vitro fertilization (IVF. AMH assay, however, is not available in all IVF Units and is quite expensive, a reason that limits its use in developing countries. The aim of this study is to assess whether the "ovarian sensitivity index" precisely reflects AMH so that this index may be used as a surrogate for AMH in prediction of ovarian response during an IVF cycle. Methods AMH serum levels were measured in 61 patients undergoing IVF with a "long" stimulation protocol including the GnRH agonist buserelin and recombinant follicle-stimulating hormone (rFSH. Patients were divided into four subgroups according to the percentile of serum AMH and their ovarian stimulation was prospectively followed. Ovarian sensitivity index (OSI was calculated dividing the total administered FSH dose by the number of retrieved oocytes. Results AMH and OSI show a highly significant negative correlation (r = -0.67; p = 0.0001 that is stronger than the one between AMH and the total number of retrieved oocytes and than the one between AMH and the total FSH dose. Conclusions OSI reflects quite satisfactory the AMH level and may be proposed as a surrogate of AMH assay in predicting ovarian responsiveness to FSH in IVF. Being very easy to calculate and costless, its use could be proposed where AMH measurement is not available or in developing countries where limiting costs is of primary importance.

  8. The Outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome in comparison with tubal factor

    Directory of Open Access Journals (Sweden)

    J. Fazel


    Full Text Available Background and purpose : Infertility with an incidence of about 15% has mainly been one of the community burdens that have even been threatening to the continuity of the family life. One of the most prevalent causes of women infertility is ovarian causes particularly PCOS. The aim of this study was to determine the outcome of IVF & ET in women with PCOS in comparison with tubal factor.Materials and methods : This was a historical cohort study performed from 1997 to 1999, at Royan Institute. 33 patients with PCOS (without any other causes of infertility who failed standard ovulation induction treatment with clomiphen citrate (≥6 cycles underwent 33 cycles of IVF & ET. Controlled group include 76 patients with only tubal factor infertility. Long protocol with Buserelin (GnRHa/HMG was used in this study.IVF & ET cycle characteristics were compared using students t-test and χ2 and Fisher’s exact test.Results : The results of this research showed that there were statistically significant difference in mean age and incidence of OHSS in two groups. Howerer there were no satistically significant differences in duration of follicular phase, the duration of GnRHa usage up to the onset of HMG, cyst number after using GnRHa, cyst aspiration percent, HMG ampoule retrieved oocyte, produced embryo per person, embryo transfer per person, cycle cancellation and pregnancy rate per embryo transfer in two groups.Conclusion : It seems that IVF & ET are successful procedures in PCOS patients resistant to other usual treatment and hormonal dysfunction of this group of patients did not affect the results.

  9. Comparison of follicular dynamics, superovulatory response, and embryo recovery between estradiol based and conventional superstimulation protocol in buffaloes (Bubalus bubalis

    Directory of Open Access Journals (Sweden)

    Narinder Singh


    Full Text Available Aim: To evaluate the follicular dynamics, superovulatory response, and embryo recovery following superstimulatory treatment initiated at estradiol-17β induced follicular wave emergence and its comparison with conventional superstimulatory protocol in buffaloes. Materials and Methods: Six normal cycling pluriparous buffaloes, lactating, 90-180 days post-partum, and weighing between 500 and 660 kg were superstimulated twice with a withdrawal period of 35 days in between two treatments. In superstimulation protocol-1 (estradiol group buffaloes were administered estradiol-17β (2 mg, i.m. and eazibreed controlled internal drug release (CIDR was inserted intravaginally (day=0 at the random stage of the estrous cycle. On the day 4, buffaloes were superstimulated using follicle stimulating hormone (FSH 400 mg, divided into 10 tapering doses given at 12 hourly intervals. Prostaglandin F2α analogs (PGF2α was administered at day 7.5 and day 8, and CIDR was removed with the second PGF2α injection. In superstimulation protocol - 2 (conventional group buffaloes were superstimulated on the 10th day of the estrous cycle with same FSH dose regimen and similar timings for PGF2α injections. In both groups, half of the buffaloes were treated with luteinizing hormone (LH 25 mg and other half with 100 ug buserelin; gonadotrophin releasing hormone (GnRH analog at 12 h after the end of FSH treatment. All buffaloes in both protocols were inseminated twice at 12 and 24 h of LH/GnRH treatment. Daily ultrasonography was performed to record the size and number of follicles and superovulatory response. Results: Significantly higher number of small follicles (8 mm, corpora lutea, and transferable embryos was higher in buffaloes superstimulated at estradiol-induced follicular wave compared to the conventional protocol: Further the percentage of transferable embryos was significantly higher in buffaloes administered with LH compared to GnRH.

  10. Simultaneous Measurement of Serum Chemical Castration Agents and Testosterone Levels Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry. (United States)

    Ko, Dae-Hyun; Lee, Kyunghoon; Jeon, Sun-Hee; Song, Sang Hoon; Yun, Yeo-Min; Chun, Sail; Kim, Hee Seung; Kim, Jin Young; In, Moon Kyo; Song, Junghan


    Chemical castration involves administration of drugs to prevent pathological sexual behavior, reduce abnormal sexual drive and treat hormone-dependent cancers. Various drugs have been used for chemical castration; however, substantial interindividual variability and side effects are often observed. In this study, we proposed a useful monitoring method for the application of chemical castration agents using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS). Testosterone, cyproterone acetate, medroxyprogesterone, goserelin acetate, leuprolide acetate and triptorelin acetate were analyzed by UPLC-MS-MS. The target drugs were extracted from serum samples by double protein precipitation using methanol. Testosterone-1,2-d2 and buserelin acetate were used as internal standards. Parameters of analytical performance were evaluated, including imprecision, linearity, ion suppression and detection capabilities. Testosterone measurements were compared with the results of immunoassays. Serum specimens from 51 subjects who underwent chemical castration were analyzed. All drugs and testosterone were well extracted and separated using our method. The method was essentially free from potential interferences and ion suppression. Within-run and between-run imprecision values were <15%. The lower limits of quantification were 0.125 and 0.5-1.0 ng/mL for testosterone and other drugs, respectively. Good correlations with pre-existing immunoassays for testosterone measurement were observed. Sera from subjects who underwent androgen deprivation therapy showed variable levels of drugs. We successfully developed a UPLC-MS-MS-based monitoring method for chemical castration. The performance of our method was generally acceptable. This method may provide a novel monitoring strategy for chemical castration to enhance expected effects while reducing unwanted side effects. PMID:26989223

  11. Improving genetic potential and fertility of dairy buffalo through appropriate management interventions

    International Nuclear Information System (INIS)

    Delayed puberty and sub-oestrus are major reproductive disorders of economic importance in buffaloes. The genetic improvement is also slow in buffaloes mainly due to preference of the farmers for natural service with bulls of unknown genetic makeup. In the present study, a survey was conducted to identify the factors responsible for delay in puberty in dairy buffaloes. Nutritional (urea molasses multi-nutrient blocks; UMMB) and hormonal interventions (equine chorionic gonadotropin; ECG) were used to hasten the onset of puberty in dairy buffaloes. Oestrus could be induced in 40 to 100% heifers with variable conception rates (0 to 100%). 'Ovsynch' protocols of oestrus synchronization followed by fixed time artificial insemination with semen of bulls of known pedigree was applied to address the problem of sub- oestrus and poor genetic potential of the herd. Twenty-seven buffaloes that failed to exhibit oestrus up to 2 years postpartum were confirmed to be in sub-oestrus for having active corpus luteum and 1.0 ng/ml plasma progesterone concentrations were subjected to ovusynch treatment protocol. Treatment was started (day 0) irrespective of the stage of oestrus cycle on the first day of examination. 20 μg buserelin (receptal 5ml; intervet) was injected intra-muscular on day 0, followed by cloprostenol 500 μg (vetmate 2ml; vet care) on day 7 and second injection of receptal (2.5 ml) on day 9. Fixed time AI was done 16 and 40 hrs thereafter. Buffaloes returning to oestrus were served naturally and pregnancy was diagnosed 90 days later. Variable signs of oestrus were observed in the buffaloes: vaginal mucus discharge in 40.7%, standing heat in 18.5%, variable degree of cervical dilatation and uterine tone in 100%. Treatment induced ovulation occurred in 88.9% buffaloes of which 51.9% conceived to the AI the overall conception rates up to three services were 66.7%. It was concluded that poor nutrition and management are major impediments for delaying onset of puberty in

  12. Fertility of Holstein heifers after two doses of PGF2α in 5-day CO-Synch progesterone-based synchronization protocol. (United States)

    Say, Erkan; Çoban, Serdal; Nak, Yavuz; Nak, Deniz; Kara, Uğur; White, Stephanie; Kasimanickam, Vanmathy; Kasimanickam, Ramanathan


    The objective of the study was to determine the effect of three different PGF2α (PGF) treatments in the 5-day CO-Synch progesterone-based synchronization protocol on artificial insemination (AI) pregnancy rate (PR) in Holstein heifers in Turkey and the United States. We hypothesized that two doses of PGF administered concurrently or 6 hours apart would result in greater AI pregnancy compared with a single dose of PGF on Day 5 at controlled internal drug release (CIDR) removal. In Turkey, Holstein heifers (n = 450) from one farm in the province of Adana and another farm in the province of Bursa were included. In the US, Holstein heifers (n = 483) from two locations in the state of Idaho were included. Heifers within locations were randomly allocated to one of three protocol groups: 1PGF-received 25 mg IM of dinoprost at CIDR removal; 2Co-PGF-received 50 mg IM of dinoprost at CIDR removal, and 2PGF-received 25 mg IM of dinoprost at CIDR removal and an additional 25 mg IM of dinoprost 6 hours later. All heifers received a CIDR (1.38 g of progesterone) and GnRH (10 μg IM of Buserelin [Turkey] or gonadorelin hydrochloride [US]) on Day 0. The CIDRs were removed on Day 5, and each heifer was given PGF according to the assigned treatments. On Day 7, each heifer was given another dose of GnRH and concurrently inseminated at 56 hours after CIDR removal. Heifers in both experiments were examined for pregnancy status between 35 and 45 days after AI. Overall, controlling for age, the heifers in the 2PGF group had greater AI-PR (61.7% [192/311]) than heifers in 2Co-PGF (48.2% [149/309]; P  0.1). In Turkey, the heifers in the 2PGF group had a greater AI-PR (60% [90/150]) than 2Co-PGF (45.3% (68/150); P  0.1). There was a trend for AI pregnancy between 1PGF and 2Co-PGF groups (P = 0.08). In the United States, the heifers in the 2PGF group had a greater AI-PR (63.4% [102/161]) than the heifers in 2PGF (50.9 [81/159]; P < 0.05) or 1PGF (52.1% [85/163]; P < 0

  13. Enhancing off-season fertility in dairy buffaloes through monensin supplementation

    International Nuclear Information System (INIS)

    Full text: 'Sub-oestrus' forms one of the major reproductive disorders in dairy buffaloes, with incidence varying between 15 and 80% causing huge economic losses to the dairy industry. Heat stress and malnutrition have been implicated among the major causative factors. The present study aimed at improving fertility of sub-oestrus dairy buffaloes through a composite application of synchronized breeding and modulation of rumen microbial environment. Ninety sub-oestrus, pleuriparous, otherwise healthy lactating Murrah buffaloes reared under semi-intensive system formed the subject of this study. They were fed ad libitum seasonal green fodder, supplemented with about 5 kg home made concentrate ration and from 1 to 2 kg wheat straw during August through March and about 15 to 20 kg green fodder supplemented with about 6 kg concentrate ration and 4 kg wheat straw in April through July. Oestrus was detected visually by the farmers. These buffaloes, 60-180 d postpartum, had failed to exhibit overt oestrus and remained un-bred. However, clinical evaluation confirmed them as cycling for having functional corpus luteum, and hence were designated as suffering from 'sub-oestrus'. To manage the menace of sub-oestrus, the buffaloes were subjected to synchronized breeding using 'ovusynch protocol' which included 5 ml Receptal (20 μg Buserelin, Intervet, Holland) on day 0, 2 ml Vetmate (500 μg cloprostenol, Vet Farma, India) on day 7 and 2.5 ml Receptal on day 9, injected intramuscularly. Fixed time artificial insemination was done 16 and 40 hours after the last injection. Some of the buffaloes which returning to oestrus about 15-21 d later was served naturally. The pregnancy was diagnosed 90 d later through rectal palpation of genitalia. In the first phase, buffaloes were synchronized and bred either in the favourable breeding season (October through March; n = 40,) or in the unfavourable season (April through July; n = 40). The first service and the overall conception rates were

  14. Sincronización de estros con GnRH y Prostaglandina F2a en vacas Holstein Friesian en confinamiento Use of GnRH and PGF2a for synchronisation of oestrus in confined dairy herds

    Directory of Open Access Journals (Sweden)

    J.F. COX


    una alternativa efectiva para enfrentar el problema de detección de estros en rebaños confinadosThe combination of GNRH and prostaglandin F2a allows the control of the luteal phase and the follicular dynamic that coexist in the ovary, facilitating precise oestrus synchronisation schemes. The study was intended to characterise the reproductive response to the use of this combination for an oestrus detection program. The study considered 423 clinically sound dairy cows, from two herds, 1 to 7 calvings and adjusted production levels from 7.500 to 12.500 Kg. Cows were confined under a free-stall system and both herds were under a sanitary and nutritional control program. Since 50 days after calving, cows received 10 µg of buserelin and those having a corpus luteum, based on ultrasound assessment 7 days later, received 0.75 mg of tiaprost. At the moment of tiaprost administration and 72 h later, milk was collected for progesterone by RIA. The results showed that 90.7% (206/227 cows had a functional corpus luteum at the moment of prostaglandin administration, 93.7% (193/206 responded with luteolysis, and that 85.0% (164/193 showed oestrus behaviour. The interval to the oestrus was 66±15.2 h with 93.9% of cows presenting oestrus between days 2 and 4, with a high percentage (54.9% presenting oestrus on day 3 after tiaprost administration. Finally, the conception rate was similar to the untreated controls (55.4% (144/269 vs. 50.3% (82/163 for treated vs. untreated respectively. No differences were found between herds in any parameter considered in the study. Based on the results, it can be concluded that the combination of GnRH and PGF2a can be an effective alternative to approach the problem of estrus detection in confined dairy herds